CAMPath and BELimumab for Transplant Tolerance in Sensitized Kidney Transplant Recipients

NCT03591380 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

3

Enrollment

OTHER

Sponsor class

Stopped Recruitment complications due to COVID-19

Conditions

Kidney Transplantation

Interventions

DRUG: Belimumab

Sponsor

University of Wisconsin, Madison

Collaborators

[object Object]
[object Object]